Join Us to discuss ways of achieving equitable access to vaccines on 17 October 2018, 11:00 at WCC 3013, Harvard Law School. Register now!
In order to achieve the objectives of global health organizations, policies must be translated into actionable provisions and agreements. The Global Healthcare Innovation Alliance Accelerator endeavors to provide tools and guidance to organizations involved in those efforts. As the founder of GHIAA, Julie Barnes-Weise began consulting for the Coalition for Epidemic Preparedness Innovations (CEPI) over a year ago.
Following the Ebola crisis and the regulatory hurdles faced by the international community for an effective response, the Coalition for Epidemic Preparedness Innovations (CEPI) was launched in 2017. CEPI’s mission is to prevent epidemics by supporting the development of vaccines against diseases with epidemic potential in cases where market incentives fail and to support the capability to respond to novel pathogens with rapid vaccine development if needed. CEPI has promoted access to epidemic vaccines to ensure the right vaccines are accessible to all people. CEPI is currently conducting a consultation on its Equitable Access policy paper with a wide range of stakeholders with the following objectives: accelerate the process from development to delivery of quality vaccines, and establish effective procurement mechanisms for vaccines to all populations.
Julie will discuss the challenges of achieving equitable access to vaccines in preparation for and in times of outbreak and CEPI’s approach in working towards its objectives.
Julia Barnes-Weise, JD, CLP
Executive Director, Global Healthcare Innovation Alliance Accelerator
Julia Barnes-Weise is the Executive Director of the Global Healthcare Innovation Alliances Accelerator (GHIAA)) a non-profit organization spun out of a program in Public Policy at Duke University, and a Senior Consultant to the Coalition for Epidemic Preparedness Innovations (CEPI).
She is a lawyer, global health policy consultant, entrepreneur and Certified Licensing Professional. Barnes-Weise is a former Director of Business Development at Glaxo Wellcome (now GSK) and has consulted for BioMatch, LLC for many years. She has decades of experience negotiating IP licenses, alliance agreements and advising companies and institutions on partnering strategies. Her educational background includes a Juris Doctor degree from the University of North Carolina, a year at the Notre Dame London Law Centre studying international trade law, a BA from Ohio Wesleyan University, and an executive educational program at Duke University’s Fuqua Business School in International Marketing Leadership.
The series is co-sponsored by the Global Access in Action, a project at Berkman Klein Center for Internet & Society at Harvard University and the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.
Lunch will be served.